F. Beck, R. Guignard, L. La-dépression-en-france, and . Santé-de-l-'homme, ) : prévalence, recours au soin et sentiment d'information de la population, p.421, 2005.

D. Hélène, C. Marie, and C. Aubry, « La prise en charge de la dépression en médecine générale de ville », Etudes et resultats, Etudes et resultats, pp.810-810, 2012.

E. Amar and D. Balsan, « Les ventes d'antidépresseurs entre, Direction de la recherche, des études, de l'évaluation et des statistiques DREES, p.36, 1980.

L. Isabelle and M. Thomas, « Facteurs de risque des épisodes dépressifs en population générale », Etudes et resultats, pp.545-545, 2006.

T. Guo, Y. Xiang, and L. Xiao, Measurement-Based Care Versus Standard Care for Major Depression: A Randomized Controlled Trial With Blind Raters, American Journal of Psychiatry, vol.172, issue.10, 2015.
DOI : 10.1176/appi.ajp.2015.14050652

M. Zimmerman, M. Posternak, and I. Chelminski, Defining Remission on the Montgomery-Asberg Depression Rating Scale, The Journal of Clinical Psychiatry, vol.65, issue.2, pp.65-163, 2004.
DOI : 10.4088/JCP.v65n0204

A. Rush, H. Kraemer, and H. Sackeim, Report by the ACNP Task Force on response and remission in major depressive disorder. », Neuropsychopharmacology 31, pp.1841-53, 2006.

J. Rush, M. H. Trivedi, and M. Hicham, The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression, The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), Clinician Rating (QIDS-C), and Self-Report (QIDS-SR): A Psychometric Evaluation in Patients with Chronic Major Depression, pp.573-83, 2003.
DOI : 10.1016/S0006-3223(02)01866-8

M. Trivedi, D. Morris, and S. Wisniewski, Clinical and Sociodemographic Characteristics Associated with Suicidal Ideation in Depressed Outpatients, The Canadian Journal of Psychiatry, vol.158, issue.9, pp.58-113, 2013.
DOI : 10.1136/jnnp.23.1.56

O. Almeida, J. Pirkis, and N. Kerse, « A randomized trial to reduce the prevalence of depression and self-harm behavior in older primary care patients. », Ann Fam Med, pp.347-56, 2012.

«. 19-inconnus and . Suicide, Connaître pour prévenir : dimensions nationales, locales et associatives », observatoire national du suicide, p.2, 2016.

A. Michael, M. Posternak, and . Zimmerman, « Is There a Delay in the Antidepressant Effect? A Meta-Analysis, J Clin Psychiatry, issue.2, pp.66-148, 2005.

. Team, Evaluation of Outcomes With Citalopram for Depression Using Measurement-Based Care in STAR*D: Implications for Clinical Practice », Am J Psychiatry, vol.163, pp.28-40, 2006.

J. Mitchell, Two-week delay in onset of action of antidepressants: new evidence, The British Journal of Psychiatry, vol.188, issue.2, pp.188-105, 2006.
DOI : 10.1192/bjp.bp.105.011692

M. Martin, J. L. Katz, . Tekell, L. Charles, and . Bowden, « Onset and Early Behavioral Effects of Pharmacologically Different Antidepressants and Placebo in Depression, Neuropsychopharmacology, vol.29, pp.566-79, 2004.

S. Kim and . Kim, « Improvement within 2 weeks later treatment outcomes in patients with depressive disorders: The CRESCEND study », Journal ofAffectiveDisorders, pp.129-183, 2011.

S. Michael, E. Thase, and . Early, Improvement in the First 2 Weeks as a Predictor of Treatment Outcome in Patients With Major Depressive Disorder: A Meta-Analysis Including 6562 Patients, J Clin Psychiatry, issue.3, pp.70-344, 2009.

F. Henket and . Seemüller, « Does early improveent triggered by antidepressants predict reponse/remission? -Analysis of dat from a naturalistic study on a large sample of inpatients with major depression, Journal ofAffectiveDisorders, pp.115-439, 2009.

S. Montgomery, D. Baldwin, and P. Blier, Which antidepressants have demonstrated superior efficacy? A review of the evidence, International Clinical Psychopharmacology, vol.22, issue.6, pp.22-323, 2007.
DOI : 10.1097/YIC.0b013e3282eff7e0

S. Manning, M. , W. C. Jackson, and D. Md, « Treatin g Depression in Primary Care: Initial and Follow-Up Treatment Strategies », CME Institute, 2014.

M. Thase and M. Thase, Are SNRIs more effective than SSRIs? A review of the current state of the controversy, Psychopharmacol Bull, issue.2, pp.4158-85, 2008.

A. Cipriani, M. Purgato, and T. Furukawa, Citalopram versus other anti-depressive agents for depression, Cochrane Database Syst Rev, vol.336, issue.7644
DOI : 10.1002/14651858.CD006534.pub2

A. Cipriani, C. Santilli, and T. Furukawa, « Escitalopram versus other antidepressive agents for depression. », Cochrane Database Syst Rev, 2009.
DOI : 10.1002/14651858.cd006532.pub2

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164382

A. Cipriani, L. Ferla, T. Furukawa, and T. , « Sertraline versus other antidepressive agents for depression. », Cochrane Database Syst Rev, 2009.
DOI : 10.1002/14651858.cd006117.pub3

M. Thase, A. Entsuah, R. Rudolph, C. Dempster, and J. Glanville, Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. » Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a metaanalysis . », Br J Psychiatry Br J Psychiatry, vol.180, issue.178, pp.396-404, 2001.

A. Bradley and A. Lenox-smith, Does adding noradrenaline reuptake inhibition to selective serotonin reuptake inhibition improve efficacy in patients with depression? A systematic review of meta-analyses and large randomised pragmatic trials, Journal of Psychopharmacology, vol.196, issue.1, 2013.
DOI : 10.1176/appi.ajp.163.1.28

A. Nakagawa, N. Watanabe, and I. Omori, Milnacipran versus other antidepressive agents for depression, Cochrane Database Syst Rev, vol.38, issue.2, 2009.
DOI : 10.1002/14651858.CD006529.pub2

M. Gahr and «. , Agomelatine in the Treatment of Major Depressive Disorder: An Assessment of Benefits and Risks, Current Neuropharmacology, vol.12, issue.5
DOI : 10.2174/1570159X12999140619122914

M. Gahr, W. Kratzer, and M. Fuchs, « Safety and tolerability of agomelatine: focus on hepatotoxicity. », Curr Drug Metab, pp.15-694, 2014.

W. Lam, S. H. Kennedy, and S. Grigoriadis, « Canadian Network for Mood and Anxiéty Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. II. Psychothérapy alone or in combination with antidepressant medication, Journal of Affective Disorders, vol.117, 2009.

M. Fava, A. J. Mda, . Rush, *. Mdb, and M. H. Trivedi, MDb and al, « Background and rationale for the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study », Clin Psychiatry, pp.457-94, 2003.

A. Tundo, R. Filippis, and L. Proietti, « Pharmacologic approaches to treatment resistant depression: Evidences and personal experience. », World J Psychiatry, septembre, vol.5, issue.3, pp.330-371, 2015.

K. Connolly and M. Thase, « If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies. », Drugs, pp.71-114, 2011.

M. Fava and A. Rush, Current Status of Augmentation and Combination Treatments for Major Depressive Disorder: A Literature Review and a Proposal for a Novel Approach to Improve Practice, Psychotherapy and Psychosomatics, vol.75, issue.3, pp.139-53, 2006.
DOI : 10.1159/000091771

W. Lam, S. H. Kennedy, and S. Grigoriadis, Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults., Journal of Affective Disorders, vol.117, pp.117-143, 2009.
DOI : 10.1016/j.jad.2009.06.041

H. Ruhé, J. Huyser, and J. Swinkels, Switching Antidepressants After a First Selective Serotonin Reuptake Inhibitor in Major Depressive Disorder, The Journal of Clinical Psychiatry, vol.67, issue.12, pp.67-1836, 2006.
DOI : 10.4088/JCP.v67n1203

. Team, Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression, pp.1231-1273, 2006.

. Team, Comparaison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients : A STAR*D Report », Am J Psychiatry, vol.163, pp.1161-72, 2006.

. Cipriani, « Lithium versus Antidepressants in the Long-Term Treatment of Unipolar Affective Disorder », The Cochrane Database of Systematic Reviews, 2006.

N. A. , C. , and M. Bauer, Acceleration and Augmentation of Antidepressants with Lithium for Depressive Disorders: Two Meta-Analyses of Randomized, Placebo-Controlled Trials, The Journal of Clinical Psychiatry, vol.68, issue.6, pp.935-975, 2007.

M. Bauer, R. Zaninelli, B. Müller-oerlinghausen, and «. , Paroxetine and Amitriptyline Augmentation of Lithium in the Treatment of Major Depression, Journal of Clinical Psychopharmacology, vol.19, issue.2, pp.19-71, 1999.
DOI : 10.1097/00004714-199904000-00012

E. Hoencamp, J. Haffmans, and W. Dijken, Lithium Augmentation of Venlafaxine: An Open-Label Trial, Journal of Clinical Psychopharmacology, vol.20, issue.5, pp.43-538, 2000.
DOI : 10.1097/00004714-200010000-00008

A. Cipriani, Lithium in the Prevention of Suicidal Behavior and All-Cause Mortality in Patients With Mood Disorders: A Systematic Review of Randomized Trials, American Journal of Psychiatry, vol.162, issue.10, p.10, 2005.
DOI : 10.1176/appi.ajp.162.10.1805

U. Lewitzka, B. Jabs, and M. Fülle, Does lithium reduce acute suicidal ideation and behavior? A protocol for a randomized, placebo-controlled multicenter trial of lithium plus Treatment As Usual (TAU) in patients with suicidal major depressive episode, BMC Psychiatry, vol.153, issue.1, pp.19-34, 2015.
DOI : 10.1111/j.1600-0447.1992.tb03257.x

T. Bschor, M. Uhr, C. Baethge, and U. Lewitzka, Acute Antidepressive Efficacy of Lithium Monotherapy, Not Citalopram, Depends on Recurrent Course of Depression, Journal of Clinical Psychopharmacology, vol.33, issue.1, pp.33-38, 2013.
DOI : 10.1097/JCP.0b013e31827b9495

A. Ashwin, C. Patkar, and . Pae, « Atypical Antipsychotic Augmentation Strategies in the Context of Guideline-Based Care for the Treatment of Major Depressive Disorder, CNS Drugs, vol.27, issue.1, 2013.

M. Bradley, E. H. Wright, R. Eiland, and . Lorenz, « Augmentation with Atypical Antipsychotics for Depression: A Review of Evidence-Based Support from the Medical Literature, Pharmacotherapy, vol.33, issue.3, pp.344-59, 2013.

R. Fleurence, « A Systematic Review of Augmentation Strategies for Patients with Major Depressive Disorder, Psychopharmacology Bulletin, vol.42, issue.3, pp.57-90, 2009.

A. J. Rothschild, A Double-Blind, Randomized Study of Olanzapine and Olanzapine/Fluoxetine Combination for Major Depression With Psychotic Features, Journal of Clinical Psychopharmacology, vol.24, issue.4, pp.365-73, 2004.
DOI : 10.1097/01.jcp.0000130557.08996.7a

C. Richard and . Shelton, « Olanzapine/fluoxetine Combination for Treatment-Resistant Depression: A Controlled Study of SSRI and Nortriptyline Resistance, The Journal of Clinical Psychiatry, vol.66, pp.10-1289, 2005.

C. Shelton, A Novel Augmentation Strategy for Treating Resistant Major Depression, American Journal of Psychiatry, vol.158, issue.1, pp.131-165, 2001.
DOI : 10.1176/appi.ajp.158.1.131

E. Michael and . Thase, Double-Blind Comparison of Olanzapine/fluoxetine Combination, Olanzapine, and Fluoxetine in Treatment-Resistant Major Depressive Disorder, The Journal of Clinical Psychiatry, vol.68, issue.2, pp.224-260, 2007.

S. W. Andersen, D. B. Clemow, and S. A. Corya, Long-Term Weight Gain in Patients Treated With Open-Label Olanzapine in Combination With Fluoxetine for Major Depressive Disorder, The Journal of Clinical Psychiatry, vol.66, issue.11, pp.1468-76, 2005.
DOI : 10.4088/JCP.v66n1118

. Ho-jun and . Seo, « Effect of Augmented Atypical Antipsychotics on Weight Change in Patients with Major Depressive Disorder in a Naturalistic Setting, Human Psychopharmacology, vol.24, issue.2, pp.135-178, 2009.

R. M. Berman, The Efficacy and Safety of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder, The Journal of Clinical Psychiatry, vol.68, issue.06, pp.843-53, 2007.
DOI : 10.4088/JCP.v68n0604

C. Nelson and G. I. Papakostas, Atypical Antipsychotic Augmentation in Major Depressive Disorder: A Meta-Analysis of Placebo-Controlled Randomized Trials, The American Journal of Psychiatry, vol.166, issue.9, 2009.

R. N. Marcus, The Efficacy and Safety of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder, Journal of Clinical Psychopharmacology, vol.28, issue.2, pp.156-65, 2008.
DOI : 10.1097/JCP.0b013e31816774f9

R. M. Berman, ABSTRACT, CNS Spectrums, vol.154, issue.04, pp.197-206, 2009.
DOI : 10.1192/bjp.154.5.672

H. Weisler, Analysis of Suicidality in Pooled Data From 2 Double-Blind, Placebo-Controlled Aripiprazole Adjunctive Therapy Trials in Major Depressive Disorder, 548?55 85 Narong Maneeton et al., « Quetiapine Monotherapy in Acute Phase for Major Depressive Disorder: A Meta-Analysis of Randomized, Placebo-Controlled Trials », p.160, 2011.
DOI : 10.4088/JCP.09m05495gre

A. J. Cutler, Extended Release Quetiapine Fumarate Monotherapy in Major Depressive Disorder, The Journal of Clinical Psychiatry, vol.70, issue.4, pp.526-565, 2009.
DOI : 10.4088/JCP.08m04592

D. Bauer, « Pooled analysis of adjunct extended-release quetiapine fumarate in patients with major depressive disorder according to ongoing SSRI or SNRI treatm, PubMed -NCBI », pp.29-45, 2014.

A. Garakani, A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder, International Clinical Psychopharmacology, vol.23, issue.5, pp.269-75, 2008.
DOI : 10.1097/YIC.0b013e328301a74c

J. Dorée, « Quetiapine Augmentation of Treatment-Resistant Depression: A Comparison with Lithium », Current Medical Research and Opinion 23, 2007.

M. Bauer, Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder, Journal of Affective Disorders, vol.151, issue.1, 2013.
DOI : 10.1016/j.jad.2013.05.079

X. Zhou, A. Ravindran, and B. Quin, Comparative Efficacy, Acceptability, and Tolerability of Augmentation Agents in Treatment-Resistant Depression, The Journal of Clinical Psychiatry, vol.76, issue.4
DOI : 10.4088/JCP.14r09204

B. Ostroff and J. C. Nelson, Risperidone Augmentation of Selective Serotonin Reuptake Inhibitors in Major Depression, The Journal of Clinical Psychiatry, vol.60, issue.4, pp.256-59, 1999.
DOI : 10.4088/JCP.v60n0410

S. Hirose and C. R. Ashby, An Open Pilot Study Combining Risperidone and a Selective Serotonin Reuptake Inhibitor as Initial Antidepressant Therapy, The Journal of Clinical Psychiatry, vol.63, issue.8, pp.733-769, 2002.
DOI : 10.4088/JCP.v63n0812

I. Gabor and . Keitner, Placebo-Controlled Trial of Risperidone Augmentation for Patients with Difficult-to-Treat Unipolar, Non-Psychotic Major Depression, Journal of Psychiatric Research, vol.43, issue.3, pp.205-219, 2009.

H. Reeves, Efficacy of Risperidone Augmentation to Antidepressants in the Management of Suicidality in Major Depressive Disorder, The Journal of Clinical Psychiatry, vol.69, issue.8, pp.1228-1336, 2008.
DOI : 10.4088/JCP.v69n0805

A. Ramy and . Mahmoud, « Risperidone for Treatment-Refractory Major Depressive Disorder: A Randomized Trial, Annals of Internal Medicine, vol.147, issue.9, pp.593-602, 2007.

M. Hyman and R. , « Effects of Risperidone Augmentation in Patients with Treatment-Resistant Depression: Results of Open-Label Treatment Followed by Double-Blind Continuation, Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology, vol.31, issue.11, pp.2505-2518, 2006.

M. C. Amore and . Jori, Faster response on amisulpride 50 mg versus sertraline 50-100 mg in patients with dysthymia or double depression: a randomized, double-blind, parallel group study, International Clinical Psychopharmacology, vol.16, issue.6, pp.317-341, 2001.
DOI : 10.1097/00004850-200111000-00001

P. Rocca, A comparison of paroxetine versus paroxetine plus amisulpride in the treatment of dysthymic disorder: efficacy and psychosocial outcomes, Psychiatry Research, vol.112, issue.2, pp.145-52, 2002.
DOI : 10.1016/S0165-1781(02)00188-9

B. Cassano and M. C. Jori, Efficacy and safety of amisulpride 50 mg versus paroxetine 20 mg in major depression: a randomized, double-blind, parallel group study, International Clinical Psychopharmacology, vol.17, issue.1, pp.27-32, 2002.
DOI : 10.1097/00004850-200201000-00004

E. Onder and U. Tural, « Faster response in depressive patients treated with fluoxetine alone than in combination with buspirone, J Affect Disord, vol.76, pp.1-3, 2003.

. Fischer, Weak antidepressant response after buspirone augmentation of serotonin reuptake inhibitors in refractory severe depression, International Clinical Psychopharmacology, vol.13, issue.2, pp.83-86, 1998.
DOI : 10.1097/00004850-199803000-00005

B. Appelberg, E. Syvälahti, and T. Koskinen, Patients With Severe Depression May Benefit From Buspirone Augmentation of Selective Serotonin Reuptake Inhibitors, The Journal of Clinical Psychiatry, vol.62, issue.6, pp.62-448, 2001.
DOI : 10.4088/JCP.v62n0608

S. Kalra and Y. Balhara, « Euthyroid depression: the role of thyroid hormone. », Recent Pat Endocr Metab Immune Drug Discov, pp.38-41, 2014.

F. Sintzel, M. Mallaret, and T. Bougerol, « Potentializing of tricyclics and serotoninergics by thyroid hormones in resistant depressive disorders. », Encephale, pp.30-267, 2004.

*. D-study-team and «. A. , Comparison of lithium and T3 augmentation followind two failed medication treatments for depression : A STAR*D report », Am J Psychiatry, vol.163, pp.1519-1549, 2006.

S. Edwards, V. Hamilton, and L. Nherera, Lithium or an atypical antipsychotic drug in the management of treatment-resistant depression: a systematic review and economic evaluation, Health Technology Assessment, vol.17, issue.54, pp.17-18, 2013.
DOI : 10.3310/hta17540

. Mischoulon, Strategies for Managing Depression Refractory to Selective Serotonin Reuptake Inhibitor Treatment: A Survey of Clinicians, The Canadian Journal of Psychiatry, vol.43, issue.5, pp.476-81, 2000.
DOI : 10.1177/070674370004500509

D. P. Horgan, . Beyond, and . Evidence, Is There a Place for Antidepressant Combinations in the Pharmacotherapy of Depression? », The Medical Journal of Australia 187, pp.198-199, 2007.

G. De-la, « Use of Antidepressant Combinations: Which, When and Why? Results of a Spanish Survey, Acta Psychiatrica Scandinavica. Supplementum, p.428, 2005.

M. Fava and A. Rush, « Current status of augmentation ans combination treatments for major depressive disorder

. Team, Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trails for depression : a STAR*D report », Am J Psychiatry, vol.163, pp.1531-1572, 2006.

N. Watanabe, I. Omori, and A. Nakagawa, Safety Reporting and Adverse-Event Profile of Mirtazapine Described in Randomized Controlled Trials in Comparison with Other Classes of Antidepressants in the Acute-Phase Treatment of Adults with Depression, CNS Drugs, vol.356, issue.26, pp.24-35, 2010.
DOI : 10.2165/11319480-000000000-00000

. Ferreri, « Benefits from Mianserin Augmentation of Fluoxetine in Patients with Major Depression Non-Responders to Fluoxetine Alone, Acta Psychiatrica Scandinavica, vol.103, issue.1, pp.66-72, 2001.

I. Karlsson, J. Godderis, . Et-carlos-augusto-de-mendonça, and . Lima, double-blind comparison of the efficacy and safety of citalopram compared to mianserin in elderly, depressed patients with or without mild to moderate dementia », Geriatric psychiatry, pp.15-295, 2000.

N. Watanabe, I. Omori, and A. Nakagawa, Mirtazapine Versus Other Antidepressants in the Acute-Phase Treatment of Adults With Major Depression, The Journal of Clinical Psychiatry, vol.69, issue.9, pp.69-1404, 2008.
DOI : 10.4088/JCP.v69n0908

L. Carpenter, Y. S. Price, and L. , « A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine, », Biol Psychiatry, vol.1551, issue.2, pp.183-191, 2002.

A. Rush, M. Trivedi, and J. Stewart, « Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. », Am J Psychiatry, issue.7, pp.168689-701, 2011.

L. Tarsitani and M. Pasquini, Compared with Fluoxetine Monotherapy, Mirtazapine plus Venlafaxine or Fluoxetine Increase Remission but Not Response in Patients with Major Depressive Disorder », Evidence-Based Mental Health 13, p.83, 2010.

P. Blier, H. Ward, and P. Tremblay, Combination of Antidepressant Medications From Treatment Initiation for Major Depressive Disorder: A Double-Blind Randomized Study, American Journal of Psychiatry, vol.167, issue.3, pp.281-88, 2010.
DOI : 10.1176/appi.ajp.2009.09020186

S. Dodd, To combine or not to combine? A literature review of antidepressant combination therapy, 1?11 125 STAR*D study team, « Medication augmentation after the failure of SSRIs for depression, pp.354-1243, 2005.
DOI : 10.1016/j.jad.2005.08.012

P. Louis, B. Gilles, and D. , « Formation médicale continue et l'évaluation des pratiques professionnelles des médecins

W. Bates, « Incidence of Adverse Drug Events and Potential Adverse Drug Events. Implications for Prevention, ADE Prevention Study Group » JAMA, vol.274, issue.1, pp.29-34, 1995.

K. Kawamoto, Improving clinical practice using clinical decision support systems: a systematic review of trials to identify features critical to success, BMJ, vol.330, issue.7494, pp.7494-765, 2005.
DOI : 10.1136/bmj.38398.500764.8F

. Osheroff, Improving Medication Use and Outcomes with Clinical Decision Support:, Clinical Decision Support Bundle, s. d

A. Fernández, A. Pinto-meza, and J. Bellón, « Is major depression adequately diagnosed and treated by general practitioners? Results from an epidemiological study. », Gen Hosp Psychiatry, pp.32-201, 2010.

G. Malhi, K. Fritz, and C. Coulston, Severity alone should no longer determine therapeutic choice in the management of depression in primary care: Findings from a survey of general practitioners, Journal of Affective Disorders, vol.152, issue.154, pp.152-154, 2014.
DOI : 10.1016/j.jad.2013.09.040

H. Sinnema, G. Franx, and J. Spijker, Delivering stepped care for depression in general practice: Results of a survey amongst general practitioners in the Netherlands, European Journal of General Practice, vol.194, issue.2, pp.221-230, 2013.
DOI : 10.3109/09540261.2011.606803

. Davis, Impact of Formal Continuing Medical Education, JAMA, vol.282, issue.9, pp.867-74, 1999.
DOI : 10.1001/jama.282.9.867

K. Shojania, A. Jennings, and A. Mayhew, Effect of point-of-care computer reminders on physician behaviour: a systematic review, Canadian Medical Association Journal, vol.182, issue.5, pp.216-241
DOI : 10.1503/cmaj.090578

T. A. Holt, M. Thorogood, and F. Griffiths, Changing Clinical Practice Through Patient Specific Reminders Available at the Time of the Clinical Encounter: Systematic Review and Meta-Analysis, Journal of General Internal Medicine, vol.76, issue.10, pp.974-84, 2012.
DOI : 10.1007/s11606-012-2025-5

«. Nendaz, Changer la pratique médicale par la formation continue : de l'efficacité de quelques stratégies », revue médicale suisse, p.42, 2005.

P. Rajasekhar, C. Rees, and C. Nixon, Factors influencing change in clinical practice, International Journal of Health Care Quality Assurance, vol.29, issue.1, pp.295-310, 2016.
DOI : 10.1108/IJHCQA-09-2014-0093

T. Forsner, J. Hansson, and M. Brommels, Implementing clinical guidelines in psychiatry: a qualitative study of perceived facilitators and barriers, BMC Psychiatry, vol.14, issue.Suppl 1, p.8, 201010-01.
DOI : 10.1136/qshc.2005.014100

J. Scheen, G. Bruwier, H. Schmitt, «. Optimalisation, . La et al., Résultats de l'étude " DREAM " en médecine générale », Rev Med Liege, vol.2, issue.58, pp.3-139, 2003.

H. Sinnema, M. C. Majo, and D. Volker, Effectiveness of a tailored implementation programme to improve recognition, diagnosis and treatment of anxiety and depression in general practice: a cluster randomised controlled trial, Implementation Science, vol.11, issue.6, p.35, 2015.
DOI : 10.1177/1094428106291059